Skip to main content
logo
Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
15.26
-0.22 (-1.42%)
Oct 12, 2026, 1:32 PM EDT - Market open

Ultragenyx Pharmaceutical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-586-575-569-607-707.42-454.03
Depreciation & Amortization
3335362618.2213.24
Asset Writedown & Restructuring Costs
----75.03-
Loss (Gain) From Sale of Investments
-2-4-13-132248.67
Stock-Based Compensation
139153158135130.38104.95
Other Operating Activities
-45-52-40-21.0911.71
Change in Accounts Receivable
-71-31-34-23-12.07-5.43
Change in Inventory
-12-6-11-7-9.7-3.12
Change in Accounts Payable
492447-179.8532.31
Change in Unearned Revenue
------57.49
Change in Other Net Operating Assets
10-1012153.8-29.51
Operating Cash Flow
-485-466-414-475-380.47-338.7
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-4-6-7-44-116.12-73.09
Cash Acquisitions
-----75.03-
Sale (Purchase) of Intangibles
-5-15-13-3-30-
Investment in Securities
532584221-69.66-121.34
Other Investing Activities
-4-1-2-6-0.84-0.94
Investing Cash Flow
40236-18168-291.65-195.37

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
58639238710.81119.04
Other Financing Activities
39239271490.4-0.49
Financing Cash Flow
397478399388501.21118.55

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-14-2--1.08-1.19
Net Cash Flow
-49252-3581-171.98-416.71

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-489-472-421-519-496.59-411.79
Free Cash Flow Growth
------
Free Cash Flow Margin
-68.20%-70.13%-75.18%-119.59%-136.68%-117.18%
Free Cash Flow Per Share
-4.86-4.79-4.65-7.06-7.10-6.07
Levered Free Cash Flow
-221.79-251.13-207-312.54-370.58-244.82
Unlevered Free Cash Flow
-173.66-212.38-167.63-271.29-343.7-226.43

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
44----
Change in Working Capital
-24-2314-1660.24-63.24
SEC Filings: 10-K · 10-Q